Trial Profile
Expanded access programme of ipilimumab in patients with pre-treated advanced uveal melanoma
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 01 Dec 2015
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary)
- Indications Uveal melanoma
- Focus Adverse reactions; Expanded access; Therapeutic Use
- 01 Dec 2015 New trial record